bioequivalence of febuxostat

Single-dose bioequivalence studies of two febuxostat tablets in healthy volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200705048005N1

Enrollment

Registered

2021-02-09

Start date

2020-03-02

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects. -

Interventions

Intervention 1: Receiving test formulation (generic product) In this study, subjects received one febuxostat tablet in each period. In the first period of the study, half of subjects received one 80 m

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Male volunteer Age: 18-50 year Healthyvolunteer

Exclusion criteria

Exclusion criteria: History of liver, kidney and cardiovascular diseases that can affect drug clearance from body Any medication prescribed in the last two weeks

Design outcomes

Primary

Measure	Time frame
Plasma drug concentration. Timepoint: 0.25 0.5 0.75 1 2 3 4 6 8 10 12 14 24. Method of measurement: HPLC method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahraz Osouli

Shahid Beheshti University of Medical Sciences

mahraz.osouli@yahoo.com02188200118 (155)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026